N-(2-tert-Butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropyl-propyl)-2-chloroacetamide | 147283-20-3

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: N-(2-tert-Butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropyl-propyl)-2-chloroacetamide
• 英文别名: 2-chloro-N-<2-<(tert-butyldimethylsilyl)oxy>-3,3,3-trifluoro-1-isopropylpropyl>acetamide；N-(2-tert-butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropylpropyl)-2-chloroacetamide；N-[2-[tert-butyl(dimethyl)silyl]oxy-1,1,1-trifluoro-4-methylpentan-3-yl]-2-chloroacetamide
• CAS: 147283-20-3
• 化学式: C₁₄H₂₇ClF₃NO₂Si
• 分子量: 361.908
• InChiKey: JYBFWBDJZFHYAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.32
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2-tert-Butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropyl-propyl)-2-chloroacetamide 在 四丁基氟化铵 、 sodium hydride 、 sodium iodide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 12.0h， 生成 benzyl N-[6-(4-methylphenyl)-2-oxo-1-[2-oxo-2-[(1,1,1-trifluoro-2-hydroxy-4-methylpentan-3-yl)amino]ethyl]pyridin-3-yl]carbamate
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015
• 作为产物：
  描述：

  3-amino-1,1,1-trifluoro-4-methyl-2-pentanol hydrochloride 在 N-甲基吗啉 、 2,6-二甲基吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 30.0h， 生成 N-(2-tert-Butyldimethylsilyloxy-3,3,3-trifluoro-1-isopropyl-propyl)-2-chloroacetamide
  参考文献：
  名称：

  人白细胞弹性蛋白酶的非肽抑制剂。1.含吡啶酮的抑制剂的设计与合成。

  摘要：

  人白细胞弹性蛋白酶（HLE）是嗜中性粒细胞产生的一种丝氨酸蛋白酶，与肺气肿和囊性纤维化等疾病有关。HLE抑制剂在这些疾病中可能具有治疗价值。结合三肽三氟甲基酮（TFMK）抑制剂2的HLE活性位点模型是由HLE和猪胰弹性蛋白酶的X射线结构创建的。对模型的分析表明，三肽具有较好的结合构象，并且可能与酶发生重要的相互作用。该信息用于辅助设计一系列新颖的含吡啶酮的非肽类HLE抑制剂，例如2- [3-[[（（苄氧基）羰基]氨基] -2-氧-1,2-二氢-1-吡啶基] -N-（3,3,3-三氟-1-异丙基-2-氧丙基）乙酰氨基化物（5b）（Ki = 280 +/- 78 nM）。活性位点模型的检查表明，在吡啶酮环的5位上的苄基取代基可能通过与酶S2口袋形成亲脂性相互作用而提高效能。一系列5-苄基吡啶酮TFMK的合成和生物学评估为这一主张提供了证据。对模型的进一步分析表明，在吡啶酮环的3-氨基上被氢键受

  DOI：

  10.1021/jm00045a014

文献信息

• Non-peptidic inhibitors of human leukocyte elastase. 4. Design, synthesis, and in vitro and in vivo activity of a series of .beta.-carbolinone-containing trifluoromethyl ketones
  作者：Chris A. Veale、James R. Jr. Damewood、Gary B. Steelman、Craig Bryant、Bruce Gomes、Joseph Williams

  DOI：10.1021/jm00001a014

  日期：1995.1

  A novel series of human leukocyte elastase (HLE) inhibitors containing the beta-carbolinone ring system are reported. The design of these trifluoromethyl ketone-based inhibitors used a combination of structural information obtained from X-ray crystallography and molecular modeling investigations. The beta-carbolinone ring in these compounds serves as a highly efficient peptidiomimetic for the P2-P3

  据报道，含有β-咔啉酮环系统的一系列新的人类白细胞弹性蛋白酶（HLE）抑制剂。这些基于三氟甲基酮的抑制剂的设计结合了从X射线晶体学和分子模型研究中获得的结构信息。这些化合物中的β-咔啉酮环可作为HLE肽基三氟甲基酮抑制剂的P2-P3区的高效拟肽模拟物。几种β-咔啉酮具有显着的体外效能，Ki值在纳摩尔范围内。使用水分子动力学模拟，已获得并讨论了通过HLE对这些抑制剂进行分子识别的现实模型。发现该系列化合物对HLE的选择性优于许多其他蛋白水解酶，
• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• Amide derivatives
  申请人：Zeneca Limited

  公开号：US05405852A1

  公开（公告）日：1995-04-11

  The present invention relates to certain novel amide ##STR1## derivatives which are pyrido[3,4-b]indol-2-ylacetamides which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these amide derivatives, processes for preparing the amide derivatives, pharmaceutical compositions containing such amide derivatives and methods for their use.

  本发明涉及某些新型酰胺##STR1##衍生物，它们是吡啶并[3,4-b]吲哚-2-基乙酰胺，是人类白细胞弹性蛋白酶（HLE）抑制剂，也称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要此类抑制时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE参与的疾病。该发明还包括在合成这些酰胺衍生物中有用的中间体，制备酰胺衍生物的方法，含有这种酰胺衍生物的药物组合物以及它们的使用方法。
• Non-peptidic Inhibitors of Human Leukocyte Elastase. 1. The Design and Synthesis of Pyridone-Containing Inhibitors
  作者：Peter Warner、Rosalyn C. Green、Bruce Gomes、Anne M. Strimpler

  DOI：10.1021/jm00045a014

  日期：1994.9

  inhibitors such as 2-[3-[[(benzyloxy)carbonyl]amino]-2-oxo- 1,2-dihydro-1-pyridyl]-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)ace tam ide (5b) (Ki = 280 +/- 78 nM). Inspection of the active site model suggested that a benzyl substituent at the 5-position of the pyridone ring might improve potency by forming a lipophilic interaction with the enzyme S2 pocket. Synthesis and biological evaluation of a series of

  人白细胞弹性蛋白酶（HLE）是嗜中性粒细胞产生的一种丝氨酸蛋白酶，与肺气肿和囊性纤维化等疾病有关。HLE抑制剂在这些疾病中可能具有治疗价值。结合三肽三氟甲基酮（TFMK）抑制剂2的HLE活性位点模型是由HLE和猪胰弹性蛋白酶的X射线结构创建的。对模型的分析表明，三肽具有较好的结合构象，并且可能与酶发生重要的相互作用。该信息用于辅助设计一系列新颖的含吡啶酮的非肽类HLE抑制剂，例如2- [3-[[（（苄氧基）羰基]氨基] -2-氧-1,2-二氢-1-吡啶基] -N-（3,3,3-三氟-1-异丙基-2-氧丙基）乙酰氨基化物（5b）（Ki = 280 +/- 78 nM）。活性位点模型的检查表明，在吡啶酮环的5位上的苄基取代基可能通过与酶S2口袋形成亲脂性相互作用而提高效能。一系列5-苄基吡啶酮TFMK的合成和生物学评估为这一主张提供了证据。对模型的进一步分析表明，在吡啶酮环的3-氨基上被氢键受
• Nonpeptidic Inhibitors of Human Neutrophil Elastase. 7. Design, Synthesis, and <i>in Vitro</i> Activity of a Series of Pyridopyrimidine Trifluoromethyl Ketones
  作者：Philip D. Edwards、Donald W. Andisik、Anne M. Strimpler、Bruce Gomes、Paul A. Tuthill

  DOI：10.1021/jm950684z

  日期：1996.1.1

  Using molecular modeling and the information derived from X-ray crystal structures of human neutrophil elastase (HNE) and porcine pancreatic elastase (PPE) complexed to peptidic ligands, we have developed a new series of nonpeptidic inhibitors of HNE, the pyridopyrimidine trifluoromethyl ketones (TFMKs). These bicyclic inhibitors were designed to extend the concept of the related pyridone trifluoromethyl ketones by incorporating a rigidly positioned carbonyl group to participate in a hydrogen bonding interaction with the backbone NH groups of Gly-218 and Gly-219 of the enzyme. In addition, the pyrimidine ring serves as a scaffold to vector substituents toward the S-5-S-4 subsites of the enzyme's extended binding pocket. Furthermore, the heteroatoms of the pyrimidine ring generally increase the aqueous solubility of the pyridopyrimidines relative to pyridone TFMKs. Pyridopyrimidine TFMKs containing a 6-phenyl substituent afforded potent inhibitors of elastase, and several inhibitors from this class of compounds possessed aqueous solubilities of > 0.1 mg/mL and K-i values of less than or equal to 10 nM.